B&A Biomedical

B&A Biomedical is a preclinical-stage biotechnology company specializing in the discovery and development of novel small molecule therapeutics for neurodegenerative disorders and oncology. Founded by industry veterans Dr. Magid Abou-Gharbia and Dr. Benjamin Blass, the company leverages extensive expertise in medicinal chemistry and structure-based drug design. Their research efforts are primarily focused on identifying disease-modifying treatments for Alzheimer's disease and Parkinson's disease, as well as targeted therapies for various cancers. B&A Biomedical operates through a collaborative model, often partnering with academic institutions like the Moulder Center for Drug Discovery Research to advance its pipeline. The company's portfolio includes modulators of the p75 neurotrophin receptor and inhibitors of amyloid-beta aggregation. By integrating industrial drug discovery practices with academic innovation, B&A Biomedical aims to address significant unmet medical needs in aging-related diseases.